IOM announces another public meeting with the Committee on Diagnostic Criteria for ME/CFS. Read more to find out how you can participate…
FDA Releases New Draft Guidance for Industry “CFS/ME: Developing Drug Products for Treatment” in order to assist sponsors in the development of drug products for the treatment of CFS/ME.
On Monday, January 27th, 2014, Carol Head, Association President and CEO was in Washington D.C. along with several other organization leaders, fellow advocates and patients to take part in the first public meeting of the IOM Committee for Diagnostic Criteria for ME/CFS. Read her full comments and access the “Road to Diagnosis” report we shared.
The CFIDS Association, along with PANDORA Org and other advocates, has been invited to make a brief presentation to the IOM Committee on ME/CFS. They want to know what primary thing they should keep in mind as they look at the research. We want YOUR thoughts so we can best represent your concerns and make the most of the open session on January 27th. TAKE OUR SURVEY
Hope on the Hill – ME/CFS in Washington DC: Our perspective on the federal government and why we continue our work.
On Tuesday, December 3, the IOM announced the provisional Clinical Case Definition Committee slate. The Association has reviewed the full slate of committee members and is optimistic that this committee can be effective in fulfilling its important mandate.
After much controversy, HHS, via the Chronic Fatigue Syndrome Advisory Committee listserv, has released an FAQ about the contract with the IOM concerning clinical diagnostic criteria development…
The next CFSAC meeting will be held via webinar on Tuesday, December 10, 2013 and Wednesday, December 11, 2013 from 12:00 p.m. until 5:00 p.m.
The Association announces it’s nominations to the CFSAC: Michael J. Decker, PhD, RN, RRT and DJ Gilbert, ME/CFS patient and advocate
On October 16 from 1:30 PM – 3:00 PM EST, FDA will hold a teleconference that is open to the public. Your voice is important in the dialogue.